Pharming Group N.V. (PHAR) Form 6-K — Oct 27, 2026
Pharming Group reported Q3 2026 total revenues of US$117.6 million, up 21% year-over-year and above market expectations, with operating profit up 89% to US$29.9 million and net profit of US$22.4 million. Joenja (leniolisib) was the standout grower at US$23.8 million (+58%), boosted by launches in Germany and Japan plus a new FDA-approved U.S. pediatric label for children aged 4-11, while RUCONEST returned to growth at US$93.8 million (+14%). The company tightened 2026 revenue guidance to US$380-390 million, raised cash to US$190.9 million, and expects Phase II topline data for leniolisib in CVID in November 2026, a potential path to a much larger indication than APDS.
Key figures
- Eps
- US$0.032 basic / US$0.030 diluted (Q3 2026)
- Revenue
- 117600000
- Guidance
- 2026 total revenues of US$380.0M-US$390.0M (tightened from US$375M-US$395M); total operating expenses of US$310.0M-US$315.0M
- Net Income
- 22400000
- Revenue Yoy
- 21%
- Cash Position
- 190900000
- Joenja q3 revenue
- US$23.8M (+58% YoY)
- Operating profit q3
- US$29.9M (+89% YoY)
- Ruconest q3 revenue
- US$93.8M (+14% YoY)
- Us joenja paid patients
- 136
- Falcon enrollment target
- ~145 of 180 subjects by end of 2026
- Int l joenja paid patients
- 75
- Adjusted operating profit q3
- US$35.0M
- Cvid phase2 topline expected
- November 2026
- Spleen volume reduction phase2
- mean 26.4%
- Pdufa lower dose pediatric snda
- January 30, 2027
- Diagnosed apds patients globally
- 1056
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.